Skip to Content
Merck
All Photos(1)

Key Documents

179M-9

Sigma-Aldrich

CD79a (JCB117) Mouse Monoclonal Antibody

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

JCB117, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (179M-94)
vial of 0.5 mL concentrate (179M-95)
bottle of 1.0 mL predilute (179M-97)
vial of 1.0 mL concentrate (179M-96)
bottle of 7.0 mL predilute (179M-98)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

isotype

IgG1κ

control

tonsil

shipped in

wet ice

storage temp.

2-8°C

visualization

membranous

Gene Information

human ... CD79A(973)

General description

Anti-CD79a is a B-cell marker that is generally used to complement CD20. This antibody will stain many of the same lymphomas as CD20, but also is more likely to stain precursor B-lymphoid leukemias than CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Anti-CD79a will stain many cases of acute promyelocytic leukemia (FAB-M3), but only rarely stains other types of myeloid leukemia.

Quality


IVD
IVD
IVD
RUO

Linkage

CD79a Positive Control Slides, Product No. 179S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

X Yao et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 14(2), 105-110 (2001-03-10)
Immunohistochemical studies are increasingly used for the routine diagnosis of lymphomas as it is widely accepted that lymphomas of different cell lineages vary in their prognosis and response to therapy. A case of peripheral T-cell lymphoma with aberrant expression of
B T Lin et al.
Human pathology, 28(9), 1083-1090 (1997-10-06)
Primary plasmacytoma of the lymph nodes is very rare, and there are fewer than 20 reported cases. These cases appeared to have a better prognosis than other extramedullary plasmacytomas, with rare recurrence and no progression to myeloma after treatment. To
D Y Mason et al.
European journal of immunology, 22(10), 2753-2756 (1992-10-01)
Surface immunoglobulin on mouse B cells is associated with a heterodimer comprising the products of the mb-1 and B29 genes. Here we report that antibodies raised against a peptide sequence from the intracytoplasmic C terminus of the B29 murine gene
K Blakolmer et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 13(7), 766-772 (2000-07-27)
The monoclonal antibodies L26 (CD20) and CD79a are very useful reagents for the immunohistochemical assessment of B-cell lineage in lymphoproliferative disorders. Although very few CD20-positive peripheral T-cell lymphomas (PTL) have been reported, comprehensive analyses of CD79a reactivity in extranodal PTL
Luis Requena et al.
Archives of dermatology, 139(4), 475-486 (2003-04-23)
Specific cutaneous involvement in patients with multiple myeloma (MM) is very uncommon. It usually occurs in late stages of MM as a reflection of increased tumor cell burden. We studied 8 patients with cutaneous involvement of MM without underlying bony
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service